These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Gambacciani M; Monteleone P; Sacco A; Genazzani AR Best Pract Res Clin Endocrinol Metab; 2003 Mar; 17(1):139-47. PubMed ID: 12763517 [TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Sjögren LL; Mørch LS; Løkkegaard E Maturitas; 2016 Sep; 91():25-35. PubMed ID: 27451318 [TBL] [Abstract][Full Text] [Related]
8. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829 [TBL] [Abstract][Full Text] [Related]
9. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. McGonigle KF; Karlan BY; Barbuto DA; Leuchter RS; Lagasse LD; Judd HL Gynecol Oncol; 1994 Oct; 55(1):126-32. PubMed ID: 7959253 [TBL] [Abstract][Full Text] [Related]
10. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897 [TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108 [TBL] [Abstract][Full Text] [Related]